Hemophilia in Children - Modern Paradigms of Treatment and Prevention

children hemophilia inhibitor substitution therapy non-factorial drugs

Authors

  • Mamatkulova Dilrabo Hamidovna Candidate of medical sciences, Associate Professor of the Department of Pediatrics № 3 and medical genetics of pediatric faculty of the Samarkand State Medical University
March 1, 2025

Downloads

World Hemophilia Day is celebrated on April 17. The date is timed to coincide with the birthday of Frank Schneibel, founder of the World Hemophilia Federation. Both on this day and on other days, the medical community is called upon to draw attention to the problems of people suffering from blood clotting disorders — one of the central problems in hematology. Although hemophilia is one of the most common genetically determined disorders of blood clotting, it is considered a rare (orphan) disease. The disease manifests itself in early childhood, has clinically the two most common variants of the disease: hemophilia A and hemophilia B. Diagnosis requires mandatory genetic confirmation or laboratory confirmation of a decrease in the concentration of factor VIII for hemophilia A and factor IX for hemophilia B. The introduction of domestic recombinant coagulation factors in recent years has made it possible to significantly optimize replacement therapy in children with hemophilia, and in the face of growing Western sanctions, to provide Russian children with the necessary urgent care and prevention tools that are not inferior to the best foreign analogues. New principles of therapy that radically change management include non-active drugs and gene therapy options for both hemophilia Aand hemophilia B.

Similar Articles

1 2 3 4 5 6 7 8 9 > >> 

You may also start an advanced similarity search for this article.